In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly faces Zyprexa class action brought by third-party payers

This article was originally published in Scrip

Executive Summary

A federal judge in New York has granted class action status to a suit filed by insurers, labour unions and pension funds, alleging that Lillywithheld information on Zyprexa (olanzapine) adverse events and disseminated misinformation about its safety and efficacy, and marketed it for uses for which is was not indicated and for patients who would have been better served by less expensive medications.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts